Esketamine Regulates Mitophagy through ULK1/FUNDC1 Signaling Pathway to Improve LPS-induced Acute Respiratory Distress Syndrome.
Current pharmaceutical design February 28, 2025 Mei Ding, Ping Pei, Weihua Liu et al. 3 citations
In a mouse model of acute respiratory distress syndrome (ARDS) induced by inhaled lipopolysaccharide, esketamine treatment reduced lung damage, improved pulmonary vascular permeability, and suppressed inflammation, oxidative stress, and apoptosis. The drug activated mitophagy through the ULK1/FUNDC1 signaling pathway. These results suggest esketamine has therapeutic potential for ARDS.